GlassScriptPhysician profile
Joseph G Crocetti
NPI 1003834581
$2,428.51
in general payments reported to CMS, 2019-2025
26 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $155 · 2021: $58.04 · 2022: $66.68 · 2023: $238 · 2024: $763 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.00 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $418.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $342.93 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Harmony Biosciences LLC | $341.86 | 2020-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.83 | 2019-2024 | Ofev |
| Avadel Cns Pharmaceuticals, LLC | $158.29 | 2024-2025 | Lumryz |
| Genentech USA, INC. | $118.14 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $108.53 | 2019-2024 | Airsupra, Tezspire, Breztri |
| Insmed, INC. | $97.10 | 2019-2025 | Brinsupri, Arikayce |
| Merck Sharp & Dohme LLC | $86.07 | 2019-2025 | Belsomra, Zerbaxa |
| Inspire Medical Systems, INC. | $69.87 | 2023-2025 | Inspire |
| Axsome Therapeutics, INC. | $64.16 | 2023-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $63.17 | 2019-2025 | Dupixent |
| United Therapeutics Corporation | $45.54 | 2019-2024 | Tyvaso |
| Abiomed | $45.16 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.83 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $35.76 | 2019-2023 | |
| Masimo Corporation | $30.99 | 2019 | |
| Mallinckrodt Hospital Products INC. | $30.11 | 2024 | Acthar |
| Mylan Specialty L.P. | $24.87 | 2019 | |
| Advanced Respiratory, INC | $22.48 | 2019 | |
| Philips North America LLC | $20.46 | 2019 | |
| Shire North American Group INC | $16.63 | 2019 | |
| Genzyme Corporation | $14.68 | 2024 | |
| Sunovion Pharmaceuticals INC. | $14.44 | 2019 | |
| Lilly USA, LLC | $14.41 | 2025 | Zepbound |
| Actelion Pharmaceuticals US, INC. | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Crocetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.